Developments in the treatment of patients with FLT3-mutated AML

Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, gives an overview of the current treatment landscape for patients with FLT3-mutated acute myeloid leukemia (AML), outlining the current standard of care and how this may change with developments made in recent years. Prof. Knapper highlights that an intensive chemotherapy backbone combined with gemtuzumab ozogamicin is believed to be an important approach for managing fit patients with FLT3 mutations; however, a prospective Phase III trial is needed to assess whether the addition of midostaurin may further improve survival outcomes. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.